This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
AMETEK (AME) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
AMETEK's (AME) first-quarter results are expected to reflect the benefits of acquisitions despite economic uncertainties.
What's in Store for Cardinal Health (CAH) in Q3 Earnings?
by Zacks Equity Research
Cardinal Health's (CAH) third-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical and Specialty Solutions segment.
Should You Buy Booking Holdings (BKNG) Ahead of Q1 Earnings?
by Zacks Equity Research
Booking Holdings' (BKNG) first-quarter 2024 results are likely to reflect strength in gross bookings, hotel room nights sold, and airline ticket units sold.
Seeking Clues to Cardinal (CAH) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Cardinal (CAH), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Should You Consider PayPal (PYPL) Ahead of Q1 Earnings?
by Zacks Equity Research
PayPal's (PYPL) first-quarter results are expected to reflect gains from its strength in Venmo, checkout experiences and BNPL solutions.
The Zacks Analyst Blog Highlights 10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorp
by Zacks Equity Research
10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorp are included in this Analyst Blog.
Factors Setting the Tone For Lantheus' (LNTH) Q1 Earnings
by Zacks Equity Research
Lantheus' (LNTH) first-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.
Here's What You Should Know About EBAY Ahead of Q1 Earnings
by Zacks Equity Research
EBAY's first-quarter 2024 performance will likely reflect strength across its advertising business amid softness in its active buyer base.
Garmin (GRMN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Garmin's (GRMN) first-quarter 2024 results are likely to reflect growing momentum across Fitness, Outdoor, Marine, Aviation and Auto OEM segments.
3 Medical Products Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here are three stocks, TXG, CAH and HOLX, which are expected to beat earnings estimates in the ongoing reporting cycle.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cencora (COR) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Cencora's (COR) second-quarter fiscal 2024 results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.
Assessing Super Micro Computer (SMCI) Ahead of Q3 Earnings
by Zacks Equity Research
Super Micro Computer's (SMCI) third-quarter fiscal 2024 performance will likely reflect strength in the Server & Storage Systems and Subsystems & Accessories segments.
ETSY Gears Up to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
ETSY's first-quarter 2024 earnings are likely to have gained from growing momentum among active buyers and active sellers.
Is Amazon (AMZN) Stock Worth Buying Ahead of Q1 Earnings?
by Zacks Equity Research
Amazon's (AMZN) first-quarter results are expected to reflect strength across its Prime program, cloud business and smart device portfolio.
Cardinal Health (CAH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Cardinal (CAH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Paramount Global (PARA) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Paramount Global's (PARA) first-quarter performance is expected to have been aided by steady growth in viewership, driven by strength in Paramount+ amid tepid advertiser demand.
What's in Store for NXP Semiconductors' (NXPI) Q1 Earnings?
by Zacks Equity Research
NXP Semiconductors' (NXPI) first-quarter results will likely reflect strength across Industrial & IoT and Mobile end markets. However, weakening demand in the Automotive segment may have been a concern.
Rising Demand Likely to Aid GE HealthCare's (GEHC) Q1 Earnings
by Zacks Equity Research
GE HealthCare's (GEHC) first-quarter results are expected to report strong organic revenue growth, banking on balanced segmental performance driven by consistent NPIs and growing customer demand.
What's in Store for Charter Communications (CHTR) in Q1 Earnings?
by Zacks Equity Research
Charter Communications' (CHTR) first-quarter 2024 performance is likely to have benefited from its expanding broadband network despite stiff competition and slow subscriber addition.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Ongoing Procedural Growth May Aid Stryker's (SYK) Q1 Earnings
by Zacks Equity Research
Stryker's (SYK) first-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.
Cardinal Health (CAH) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
Cardinal Health (CAH) closed the most recent trading day at $103.37, moving +0.53% from the previous trading session.
What's in Store for STMicroelectronics (STM) in Q1 Earnings?
by Zacks Equity Research
STMicroelectronics' (STM) first-quarter results are expected to reflect strength in the automotive market. However, weakening demand across the personal electronics market is a concern.
Philips' (PHG) Zenition 30 to Boost Image-Guided Surgeries
by Zacks Equity Research
Philips (PHG) announces the FDA clearance for its Zenition 30 mobile C-arm, which is intended to aid in image-guided procedures at a relatively affordable cost.